Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 14, 2026 at 9:45 a.m. PT.
Investors can access a live audio webcast via the company's Investors page at ir.kyvernatx.com. A replay will be available on the website for 30 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – KYTX
On the day this news was published, KYTX declined 7.30%, reflecting a notable negative market reaction. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $38M from the company's valuation, bringing the market cap to $480M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KYTX fell 6.7% while close peers showed mixed moves (e.g., CABA -0.67%, ELTX -0.25%, NTHI +4.84%, TLSA +6.67%), pointing to stock-specific pressure rather than a broad sector swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Equity offering priced | Negative | -32.5% | Underwritten public offering of 13,333,333 shares at $7.50 per share. |
| Dec 15 | Equity offering proposed | Negative | +23.2% | Proposed $100,000,000 common stock offering with 30-day underwriter option. |
| Dec 15 | Clinical data update | Positive | +23.2% | Positive topline Phase 2 KYSA-8 data in stiff person syndrome with strong efficacy. |
| Dec 14 | Data call scheduled | Positive | +23.2% | Announcement of webcast to review registrational KYSA-8 topline results. |
| Nov 12 | Earnings and update | Positive | +4.7% | Q3 2025 business update with clinical progress and strengthened financing position. |
Recent news has driven strong price swings: positive clinical and financing updates often saw large moves, with one notable divergence on a proposed offering.
Over the last few months, Kyverna has combined major clinical and financing milestones. On Nov 12, 2025, Q3 2025 results highlighted $171.1M in cash and a loan facility up to $150M, supporting a runway into 2027. Subsequent 8-Ks detailed positive KYSA-6 and KYSA-8 data and plans for a BLA in 1H 2026. In mid-December, Kyverna announced and then priced a $100M equity offering. Against this backdrop, the J.P. Morgan conference appearance fits into an active communication and capital-raising phase.
Market Pulse Summary
The stock moved -7.3% in the session following this news. A negative reaction despite neutral conference news fits a pattern where recent financing and insider activity influenced sentiment. The December $100M offering and reported insider sale added supply and raised dilution concerns, even as clinical data remained positive. In such a backdrop, investors may have used liquidity around the J.P. Morgan appearance to reassess risk, especially with shares still trading above the 200‑day MA and well below the 52‑week high.
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT.
A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
FAQ
When will Kyverna Therapeutics (KYTX) present at the J.P. Morgan 2026 Healthcare Conference?
Who is presenting for Kyverna Therapeutics (KYTX) at the J.P. Morgan 2026 conference?
How can investors watch the Kyverna (KYTX) presentation on January 14, 2026?
Will there be a replay of the Kyverna (KYTX) J.P. Morgan presentation and for how long?
What type of content will Kyverna (KYTX) likely cover at the J.P. Morgan 2026 Healthcare Conference?
Where can I find the Kyverna (KYTX) webcast if I miss the live presentation on January 14, 2026?
